![Paul Lammers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Lammers
Directeur Général chez
Triumvira Immunologics, Inc.
Fortune : 3 942 $ au 30/09/2026
Profil
Paul Lammers is President, Chief Executive Officer & Director at Triumvira Immunologics, Inc. since 2018.
Dr. Lammers is Director at ImmunoMet Therapeutics, Inc. since 2017.
Dr. Lammers is Independent Director at Decoy Therapeutics, Inc. since 2019.
Formerly, Dr. Lammers was President, Chief Executive Officer & Director at Mirna Therapeutics, Inc. from 2009 to 2017.
Dr. Lammers was Lead Independent Director at Salarius Pharmaceuticals, Inc. Dr. Lammers was President at Repros Therapeutics, Inc. in 2009.
Dr. Lammers was Chief Medical Officer at EMD Serono, Inc. from 2002 to 2008.
Dr. Lammers completed graduate and doctorate degrees at Radboud University Nijmegen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,11 % | 31/08/2026 | 2 001 ( 0,11 % ) | 3 942 $ | 30/09/2026 |
Postes actifs de Paul Lammers
| Sociétés | Poste | Début |
|---|---|---|
ImmunoMet Therapeutics, Inc.
 ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops drugs for the treatment of cancer | Directeur/Membre du Conseil | 28/11/2017 |
Triumvira Immunologics, Inc.
 Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Directeur Général | 01/01/2018 |
Anciens postes connus de Paul Lammers
| Sociétés | Poste | Fin |
|---|---|---|
Mirna Therapeutics, Inc.
 Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Directeur Général | 01/08/2017 |
| REPROS THERAPEUTICS INC | President | 28/10/2009 |
EMD Serono, Inc.
 EMD Serono, Inc. BiotechnologyHealth Technology Develops therapeutics and drug delivery devices for neurology, oncology & immunology | Directeur Technique/Scientifique/R&D | 01/09/2008 |
| DECOY THERAPEUTICS INC. | Directeur/Membre du Conseil | - |
Formation de Paul Lammers
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
68
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Repros Therapeutics, Inc.
 Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs to treat hormonal and reproductive system disorders | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. BiotechnologyHealth Technology Develops therapeutics and drug delivery devices for neurology, oncology & immunology | Health Technology |
Radboud University Nijmegen
 Radboud University Nijmegen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Commercial Services |
ImmunoMet Therapeutics, Inc.
ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops drugs for the treatment of cancer | Health Technology |
Triumvira Immunologics, Inc.
Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Salarius Pharmaceuticals, Inc.
 Salarius Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on developing treatment for cancer | Health Technology |
